Breast cancer drug trials expanded fivefold over 25 years study finds
Annual launches of breast cancer clinical trials rose dramatically between 2000 and 2025, but reporting gaps have continued to persist, according to a systematic review.
FTMQ Health, written by our newsroom0 views
Annual initiations of clinical drug and biological therapy trials for female breast cancer expanded more than fivefold between 2000 and 2025, Bioengineer.org reported. A systematic review examined four major public clinical trial registries and identified 8,224 eligible interventional trials. These registered studies accounted for a total enrollment of 1,853,069 participants. [1]
Annual trial launches grew from 87 studies in 2000 to 472 studies in 2025, according to Bioengineer.org. The systematic review highlighted a major expansion in clinical drug development across the 26-year period. However, the report noted that reporting gaps continued to persist despite the rise in trial numbers. [1]
Cancer treatments encompass a wide range of therapies tailored to specific types of cancer, including surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. As FTMQ Health reported earlier, regulators approved a new breast cancer medication named Wilserdly, also known as giredestrant, to expand available options. FTMQ Health also reported that a United Kingdom trial is testing a five-day radiotherapy schedule across 39 hospitals. [2][4][5]
In short
- Annual breast cancer clinical drug trials rose from 87 in 2000 to 472 in 2025.
- A systematic review evaluated 8,224 interventional trials representing 1,853,069 registered participants.
- Researchers identified persistent reporting gaps despite the overall expansion in trial launches.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Global Breast Cancer Drug Trials Surged Fivefold While Reporting Gaps PersistedBioengineer.org, 17h ago (the report this story comes from)
Background
- [2]Cancer treatment on Wikipedia
- [3]António de Oliveira Salazar on Wikipedia
- [4]FDA approves new Roche breast cancer drug Wilserdly FTMQ Health, 4d ago
- [5]NHS trial tests five day radiotherapy course for breast cancer FTMQ Health, 19d ago
Our newsroom writes these reports with the help of software, from the 5 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- CAR T cell therapy analysis reveals high inflammation but low mortalityMedical Science, 3d ago
- RIPK1 Inhibitors Match Placebo Safety in Human Clinical TrialsMedical Science, 5d ago
- Phase III breast cancer study tests reduced post surgery therapyMedical Science, 24d ago
- Researchers publish framework to improve outcome definitions in clinical trialsMedical Science, 30d ago
- NHS trial tests five day radiotherapy course for breast cancerMedical Science, 19d ago
More in Medical Science
- Study finds high co-infection rates among malaria patients in Peshawar15h ago
- Current malaria criteria miss severe kidney injury risks in children1d ago
- CAR T cell therapy analysis reveals high inflammation but low mortality3d ago
- Diets rich in dairy and fruit linked to child height growth4d ago
- Meningococcal B vaccine prompts immune responses against gonorrhea in trial5d ago
- RIPK1 Inhibitors Match Placebo Safety in Human Clinical Trials5d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.